There are several lawsuits filed against the manufacturer of Invokana alleging that they were not warned of the life-threatening risks the new-generation diabetes drug posed, and that the manufacturer should have included warnings on the label. Invokana (canagliflozin) is one of several “new generation” type 2 diabetes drugs known as SGLT2 inhibitors approved on March 29, 2013 by U.S Food and Drugs Administration. The drug inhibits normal kidney function to allow patients to pass excess blood glucose through urination. It is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. Janssen also markets Invokamet, a combination of canagliflozin and metformin.
In a recent diabetic ketoacidosis lawsuit, a woman from Arizona filed the lawsuit on 25th July in the U.S. District Court for the District of New Jersey. She accuses drug makers Johnson & Johnson, their Janssen Pharmaceuticals subsidiary, and Mitsubishi Tanabe Pharma Corp of fully disclosing the risks associated with the drug and falsely marketing it. She claims that the drug makers betrayed her and other patients into believing Invokana was safe by their willful failure to warn of severe diabetic ketoacidosis side effects and the potential adverse event associated with the drug. Diabetic ketoacidosis is an accumulation of acids called ketones in the blood. It is the most dangerous potential side effect of Invokana.
Although Invokana was approved by the United States Food and Drug Administration at the end of March in 2013 it associated with several life threatening complications, the FDA has issued a follow-up side effect warning in May of this year to inform patients and doctors about the health risks linked with Invokana medication. The complications include;
- Diabetic Ketoacidosis or Acidosis
- Kidney Failure or Kidney Complications
- Heart Attack or Stroke
- Urinary Tract Infections
- Bone Fractures
- Blood Infection
As per Food and Drug Administration (FDA) reports, more than 50 patients who were on Invokana medication discontinued the medications and saw some improvement, but it warned that kidney injury is not reversible in all situations. FDA advised that before prescribing Invokana or Farxiga, physicians and healthcare providers should screen patients for aspects that might incline them to kidney injury.
Other drugs of SGLT2 inhibitors class include:
Sodium glucose transporter 2 (SGLT2) inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. SGLT2 inhibitors are attractive agents in managing diabetes cause of their additional beneficial effects on blood pressure and lipids. SGLT2 inhibitors work by preventing the kidneys from reabsorbing glucose back into the blood. The drugs belong to the SGLT2 inhibitors class are:
- Farxiga (dapagliflozin)
- Xigduo XR (dapagliflozin and metformin extended-release)
- Invokamet (canagliflozin and metformin)
- Jardiance (empagliflozin)
- Glyxambi (empagliflozin and linagliptin)
Allegations against the Invokana Manufacturer
In a series of new Invokana lawsuits according to plaintiffs the drug’s manufacturer did nothing. Rather than warn the public, Janssen Pharmaceuticals, a subsidiary of corporate giant Johnson & Johnson, actively defended its product and failed to provide adequate warnings and communications to the medical community and end line consumers of the increased risk of serious and life threatening medical complications associated with these drugs. Invokana has been linked to kidney problems, ketoacidosis, coma, and heart attack. Thousands of lawsuits have been filed against Johnson & Johnson, Janssen Pharmaceutical, and their affiliated companies. In all the lawsuits the allegations are similar. The lawsuits allege;
- The manufacturers Fails to warn patients of the risks associated with Invokana.
- Manufacturer negligence for safety.
- Manufacturing defects in the drug.
- Misinterpretation of marketed risks and benefits.
- The drug is not properly tested before going to market.
- Fraudulent misrepresentation and concealing evidence.
- The manufacturers of Invokana knew that the drug could cause diabetic ketoacidosis.
How to file an Invokana lawsuit?
Any patient who was prescribed Invokana and then suffered from ketoacidosis, kidney failure, Heart Attack or Stroke may be eligible to file a personal injury lawsuit against the drug’s manufacturer. The Drugsclaim Lawyers and Attorneys are investigating claims that Invokana may be linked to kidney failure, cardiovascular complications and bone fractures. In filing personal injury lawsuits, injured patients seek compensation for medical expenses, lost work and pain and suffering, among other damages.